CA2704549A1 - Use of oligonucleotides with modified bases as antiviral agents - Google Patents

Use of oligonucleotides with modified bases as antiviral agents Download PDF

Info

Publication number
CA2704549A1
CA2704549A1 CA2704549A CA2704549A CA2704549A1 CA 2704549 A1 CA2704549 A1 CA 2704549A1 CA 2704549 A CA2704549 A CA 2704549A CA 2704549 A CA2704549 A CA 2704549A CA 2704549 A1 CA2704549 A1 CA 2704549A1
Authority
CA
Canada
Prior art keywords
compound
oligonucleotide
modified
virus
oligonucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2704549A
Other languages
English (en)
French (fr)
Inventor
Mart Saarma
Andres Merits
Mati Karelson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baltic Technology Development Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2704549A1 publication Critical patent/CA2704549A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3511—Conjugate intercalating or cleaving agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA2704549A 2007-11-05 2008-11-05 Use of oligonucleotides with modified bases as antiviral agents Abandoned CA2704549A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US98554807P 2007-11-05 2007-11-05
US60/985,548 2007-11-05
US5768508P 2008-05-30 2008-05-30
US61/057,685 2008-05-30
PCT/FI2008/050633 WO2009060122A2 (en) 2007-11-05 2008-11-05 Use of oligonucleotides with modified bases as antiviral agents

Publications (1)

Publication Number Publication Date
CA2704549A1 true CA2704549A1 (en) 2009-05-14

Family

ID=40551515

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2704549A Abandoned CA2704549A1 (en) 2007-11-05 2008-11-05 Use of oligonucleotides with modified bases as antiviral agents

Country Status (10)

Country Link
US (1) US20110171287A1 (enExample)
EP (1) EP2212420A2 (enExample)
JP (1) JP5710977B2 (enExample)
CN (1) CN101970662A (enExample)
AU (1) AU2008324066A1 (enExample)
BR (1) BRPI0819191A2 (enExample)
CA (1) CA2704549A1 (enExample)
MX (1) MX2010004983A (enExample)
WO (1) WO2009060122A2 (enExample)
ZA (1) ZA201003234B (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009060124A2 (en) * 2007-11-05 2009-05-14 Baltic Technology Development, Ltd. Use of oligonucleotides with modified bases in hybridization of nucleic acids
US8097712B2 (en) 2007-11-07 2012-01-17 Beelogics Inc. Compositions for conferring tolerance to viral disease in social insects, and the use thereof
WO2009144365A1 (en) * 2008-05-30 2009-12-03 Baltic Technology Development, Ltd. Use of oligonucleotides with modified bases as antiviral agents
US8962584B2 (en) 2009-10-14 2015-02-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Compositions for controlling Varroa mites in bees
PE20130649A1 (es) 2010-03-08 2013-07-13 Monsanto Technology Llc Moleculas polinucleotidicas para regulacion genetica en plantas
EP2755466A4 (en) 2011-09-13 2015-04-15 Monsanto Technology Llc METHOD AND COMPOSITIONS FOR WEED CONTROL
US10829828B2 (en) 2011-09-13 2020-11-10 Monsanto Technology Llc Methods and compositions for weed control
MX343072B (es) 2011-09-13 2016-10-21 Monsanto Technology Llc Metodos y composiciones para controlar malezas.
AU2012308737B2 (en) 2011-09-13 2018-06-14 Monsanto Technology Llc Methods and compositions for weed control
US9840715B1 (en) 2011-09-13 2017-12-12 Monsanto Technology Llc Methods and compositions for delaying senescence and improving disease tolerance and yield in plants
WO2013040116A1 (en) 2011-09-13 2013-03-21 Monsanto Technology Llc Methods and compositions for weed control
CN103930549B (zh) 2011-09-13 2020-09-18 孟山都技术公司 用于杂草控制的方法和组合物
US10760086B2 (en) 2011-09-13 2020-09-01 Monsanto Technology Llc Methods and compositions for weed control
CA2848669A1 (en) 2011-09-13 2013-03-21 Monsanto Technology Llc Methods and compositions for weed control targeting epsps
US10806146B2 (en) 2011-09-13 2020-10-20 Monsanto Technology Llc Methods and compositions for weed control
EP3434779A1 (en) 2011-09-13 2019-01-30 Monsanto Technology LLC Methods and compositions for weed control
CN103957697B (zh) 2011-09-13 2017-10-24 孟山都技术公司 用于杂草控制的方法和组合物
US9920326B1 (en) 2011-09-14 2018-03-20 Monsanto Technology Llc Methods and compositions for increasing invertase activity in plants
US10240162B2 (en) 2012-05-24 2019-03-26 A.B. Seeds Ltd. Compositions and methods for silencing gene expression
WO2013185067A1 (en) * 2012-06-08 2013-12-12 Shire Human Genetic Therapies, Inc. Nuclease resistant polynucleotides and uses thereof
FI3622810T3 (fi) 2012-09-24 2024-03-21 Seminis Vegetable Seeds Inc Menetelmät ja koostumukset kasvituotteiden säilyvyyden pidentämiseksi
AR093058A1 (es) 2012-10-18 2015-05-13 Monsanto Technology Llc Metodos y composiciones para el control de pestes en plantas
US10260089B2 (en) 2012-10-29 2019-04-16 The Research Foundation Of The State University Of New York Compositions and methods for recognition of RNA using triple helical peptide nucleic acids
FR2997705B1 (fr) * 2012-11-08 2015-10-16 Nicolas Ugolin Nucleotide 3' bloquant la traduction des proteines (sasb)
UA118841C2 (uk) 2013-01-01 2019-03-25 Ей.Бі. СІДС ЛТД. Спосіб формування рослини, яка має підвищену стійкість до комахи-шкідника
US10683505B2 (en) 2013-01-01 2020-06-16 Monsanto Technology Llc Methods of introducing dsRNA to plant seeds for modulating gene expression
US20150342192A1 (en) 2013-01-15 2015-12-03 Monsanto Technology Llc Methods and Compositions for Plant Pest Control
US10000767B2 (en) 2013-01-28 2018-06-19 Monsanto Technology Llc Methods and compositions for plant pest control
EP2967082A4 (en) 2013-03-13 2016-11-02 Monsanto Technology Llc METHOD AND COMPOSITIONS FOR WEED CONTROL
WO2014164761A1 (en) 2013-03-13 2014-10-09 Monsanto Technology Llc Methods and compositions for weed control
US20140283211A1 (en) 2013-03-14 2014-09-18 Monsanto Technology Llc Methods and Compositions for Plant Pest Control
US10568328B2 (en) 2013-03-15 2020-02-25 Monsanto Technology Llc Methods and compositions for weed control
US9850496B2 (en) 2013-07-19 2017-12-26 Monsanto Technology Llc Compositions and methods for controlling Leptinotarsa
JP6668236B2 (ja) 2013-07-19 2020-03-18 モンサント テクノロジー エルエルシー Ｌｅｐｔｉｎｏｔａｒｓａ防除用組成物及びその方法
MX390055B (es) 2013-11-04 2025-03-20 Monsanto Technology Llc Composiciones y metodos para controlar infestaciones de plagas y parasitos de los artropodos.
UA119253C2 (uk) 2013-12-10 2019-05-27 Біолоджикс, Інк. Спосіб боротьби із вірусом у кліща varroa та у бджіл
CN105979770B (zh) 2014-01-15 2019-07-05 孟山都技术公司 用于使用epsps多核苷酸的杂草控制的方法和组合物
BR112016022711A2 (pt) 2014-04-01 2017-10-31 Monsanto Technology Llc composições e métodos para controle de pragas de inseto
WO2015200223A1 (en) 2014-06-23 2015-12-30 Monsanto Technology Llc Compositions and methods for regulating gene expression via rna interference
US11807857B2 (en) 2014-06-25 2023-11-07 Monsanto Technology Llc Methods and compositions for delivering nucleic acids to plant cells and regulating gene expression
AU2015296700B2 (en) 2014-07-29 2021-10-21 Monsanto Technology Llc Compositions and methods for controlling insect pests
WO2016028940A1 (en) * 2014-08-19 2016-02-25 Northwestern University Protein/oligonucleotide core-shell nanoparticle therapeutics
US10968449B2 (en) 2015-01-22 2021-04-06 Monsanto Technology Llc Compositions and methods for controlling Leptinotarsa
US10883103B2 (en) 2015-06-02 2021-01-05 Monsanto Technology Llc Compositions and methods for delivery of a polynucleotide into a plant
EP3302030A4 (en) 2015-06-03 2019-04-24 Monsanto Technology LLC METHOD AND COMPOSITIONS FOR INTRODUCING NUCLEIC ACIDS IN PLANTS
EP3408390A4 (en) 2016-01-26 2019-10-09 Monsanto Technology LLC COMPOSITIONS AND METHODS FOR COMBATING INSECTS
JP2025519296A (ja) * 2022-06-13 2025-06-26 フィクレッティン サヒン 抗ウイルス効果のためのルテチウム塩化合物の使用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT62944A (en) * 1989-12-04 1993-06-28 Isis Pharmaceuticals Inc Inhibition of papilloma virus with opposite oligonucleotides
EP0724447B1 (en) * 1991-10-24 2003-05-07 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake
US5684149A (en) * 1993-01-22 1997-11-04 Research Foundation Of State University Of New York Metal complexes for promoting catalytic cleavage of RNA by transesterification
DE4415370A1 (de) * 1994-05-02 1995-11-09 Hoechst Ag Modifizierte Oligonukleotide, deren Herstellung sowie deren Verwendung
US20040171030A1 (en) * 1996-06-06 2004-09-02 Baker Brenda F. Oligomeric compounds having modified bases for binding to cytosine and uracil or thymine and their use in gene modulation
US20030064944A1 (en) * 2001-06-21 2003-04-03 Isis Pharmaceuticals Inc. Antisense modulation of transforming growth factor beta receptor II expression
AU2003241621A1 (en) * 2002-05-24 2003-12-12 Isis Pharmaceuticals, Inc. Oligonucleotides having modified nucleoside units
AU2003248708A1 (en) * 2002-06-17 2003-12-31 Isis Pharmaceuticals, Inc. Oligomeric compounds that include carbocyclic nucleosides and their use in gene modulation
AU2006216493A1 (en) * 2005-02-24 2006-08-31 Coley Pharmaceutical Gmbh Immunostimulatory oligonucleotides
MX2008014005A (es) * 2006-05-03 2009-01-27 Baltic Technology Dev Ltd Agentes antisentido que combinan un oligonucleotido modificado con base fuertemente unida y nucleasa artificial.

Also Published As

Publication number Publication date
MX2010004983A (es) 2010-07-29
ZA201003234B (en) 2011-06-29
AU2008324066A1 (en) 2009-05-14
US20110171287A1 (en) 2011-07-14
JP2011502501A (ja) 2011-01-27
JP5710977B2 (ja) 2015-04-30
WO2009060122A2 (en) 2009-05-14
BRPI0819191A2 (pt) 2017-03-21
CN101970662A (zh) 2011-02-09
EP2212420A2 (en) 2010-08-04
WO2009060122A3 (en) 2009-06-25

Similar Documents

Publication Publication Date Title
US20110171287A1 (en) Use of Oligonucleotides with Modified Bases as Antiviral Agents
Alvarez-Salas Nucleic acids as therapeutic agents
AU2008324068A1 (en) Use of oligonucleotides with modified bases in hybridization of nucleic acids
WO2013159109A1 (en) Modulation of hepatitis b virus (hbv) expression
CA2493949A1 (en) Modified small interfering rna molecules and methods of use
JP7634542B2 (ja) Ｂ型肝炎ウイルス感染症を処置するためのｓｅｐｔ９阻害剤の使用
AU2007245599A1 (en) Antisense agents combining strongly bound base - modified oligonucleotide and artificial nuclease
JP5383186B2 (ja) Ｈ１９をダウンレギュレートする核酸薬剤、及びそれを使用する方法
JP2025166835A (ja) Ｂ型肝炎ウイルス感染を処置するためのｓｃａｍｐ３阻害剤の使用
WO2022038211A2 (en) Use of a1cf inhibitors for treating hepatitis b virus infection
Schubert et al. Oligonucleotide-based antiviral strategies
JP2025094072A (ja) Ｂ型肝炎ウイルス感染を処置するためのｃｏｐｓ３阻害剤の使用
JP2023506954A (ja) Ｂ型肝炎ウイルス感染を処置するためのｓａｒａｆ阻害剤の使用
WO2009144365A1 (en) Use of oligonucleotides with modified bases as antiviral agents
WO2021122910A1 (en) Use of sbds inhibitors for treating hepatitis b virus infection
TW202313977A (zh) 作為新穎基因靜默技術的短雙股ｄｎａ及其應用
HK40077333A (en) Use of saraf inhibitors for treating hepatitis b virus infection
HK40078456A (en) Use of sbds inhibitors for treating hepatitis b virus infection
HK40071185A (en) Use of sept9 inhibitors for treating hepatitis b virus infection
HK40078459A (en) Use of scamp3 inhibitors for treating hepatitis b virus infection
WO2005082921A1 (en) Method for inhibiting cellular proliferation

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20131105

FZDE Discontinued

Effective date: 20160921